Bart Reymen

3.4k total citations
69 papers, 2.3k citations indexed

About

Bart Reymen is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Radiation. According to data from OpenAlex, Bart Reymen has authored 69 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Pulmonary and Respiratory Medicine, 37 papers in Radiology, Nuclear Medicine and Imaging and 20 papers in Radiation. Recurrent topics in Bart Reymen's work include Lung Cancer Diagnosis and Treatment (36 papers), Radiomics and Machine Learning in Medical Imaging (25 papers) and Medical Imaging Techniques and Applications (24 papers). Bart Reymen is often cited by papers focused on Lung Cancer Diagnosis and Treatment (36 papers), Radiomics and Machine Learning in Medical Imaging (25 papers) and Medical Imaging Techniques and Applications (24 papers). Bart Reymen collaborates with scholars based in Netherlands, Belgium and Denmark. Bart Reymen's co-authors include Philippe Lambin, Wouter van Elmpt, Angela van Baardwijk, Dirk De Ruysscher, Rinus Wanders, Anne‐Marie C. Dingemans, Dirk De Ruysscher, Ralph T. H. Leijenaar, Ruud Houben and Gerben Bootsma and has published in prestigious journals such as JNCI Journal of the National Cancer Institute, Clinical Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Bart Reymen

65 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bart Reymen Netherlands	27	1.3k	1.1k	573	451	374	69	2.3k
Carlo Greco Italy	25	1.2k 0.9×	1.0k 0.9×	466 0.8×	758 1.7×	402 1.1×	141	2.4k
Oliver Riesterer Switzerland	29	906 0.7×	1.2k 1.0×	621 1.1×	386 0.9×	373 1.0×	107	2.4k
Bernard Dubray France	30	1.6k 1.2×	1.4k 1.3×	465 0.8×	1.1k 2.5×	300 0.8×	119	3.1k
Kyle C. Cuneo United States	29	648 0.5×	571 0.5×	666 1.2×	346 0.8×	432 1.2×	111	2.4k
Raquibul Hannan United States	28	1.3k 1.0×	460 0.4×	637 1.1×	463 1.0×	366 1.0×	110	2.1k
Ralph A. Bundschuh Germany	33	1.3k 1.0×	2.7k 2.4×	701 1.2×	359 0.8×	108 0.3×	138	3.5k
Gillian C. Barnett United Kingdom	22	728 0.6×	994 0.9×	535 0.9×	545 1.2×	684 1.8×	41	2.1k
Rodney J. Ellis United States	25	1.1k 0.8×	582 0.5×	189 0.3×	530 1.2×	165 0.4×	106	1.8k
Imran Zoberi United States	26	512 0.4×	812 0.7×	306 0.5×	678 1.5×	450 1.2×	91	2.0k
C. Bourgier France	31	1.1k 0.8×	791 0.7×	1.2k 2.2×	517 1.1×	1.2k 3.2×	163	3.1k

Countries citing papers authored by Bart Reymen

Since Specialization

Citations

This map shows the geographic impact of Bart Reymen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart Reymen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart Reymen more than expected).

Fields of papers citing papers by Bart Reymen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bart Reymen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart Reymen. The network helps show where Bart Reymen may publish in the future.

Co-authorship network of co-authors of Bart Reymen

This figure shows the co-authorship network connecting the top 25 collaborators of Bart Reymen. A scholar is included among the top collaborators of Bart Reymen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bart Reymen. Bart Reymen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ruysscher, Dirk De, Bart Reymen, Maarten Lambrecht, et al.. (2023). 18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial. Radiotherapy and Oncology. 181. 109492–109492. 25 indexed citations

Vansteenkiste, Johan, Els Wauters, Bart Reymen, et al.. (2019). Current status of immune checkpoint inhibition in early-stage NSCLC. Annals of Oncology. 30(8). 1244–1253. 96 indexed citations

Loon, J. Van, Dirk De Ruysscher, Sophie Peeters, et al.. (2018). PV-0039: Outcome of elderly NSCLC patients treated with isotoxic RT dose-escalation using IMRT (NCT01166204). Radiotherapy and Oncology. 127. S15–S16. 1 indexed citations

Ruysscher, Dirk De, Rinus Wanders, Lizza Hendriks, et al.. (2018). Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450). Journal of Thoracic Oncology. 13(12). 1958–1961. 63 indexed citations

Diessen, Judi van, Dirk De Ruysscher, Jan‐Jakob Sonke, et al.. (2018). The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial). Radiotherapy and Oncology. 131. 166–173. 53 indexed citations

Slotman, Ben J., Corinne Faivre‐Finn, Harm van Tinteren, et al.. (2017). Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial. Lung Cancer. 108. 150–153. 60 indexed citations

Even, Aniek J.G., J. van der Stoep, Catharina M.L. Zegers, et al.. (2015). PET-based dose painting in non-small cell lung cancer: Comparing uniform dose escalation with boosting hypoxic and metabolically active sub-volumes. Radiotherapy and Oncology. 116(2). 281–286. 54 indexed citations

Zegers, Catharina M.L., Wouter van Elmpt, Bart Reymen, et al.. (2014). In Vivo Quantification of Hypoxic and Metabolic Status of NSCLC Tumors Using [18F]HX4 and [18F]FDG-PET/CT Imaging. Clinical Cancer Research. 20(24). 6389–6397. 69 indexed citations

Reymen, Bart, Angela van Baardwijk, Rinus Wanders, et al.. (2014). Long-term survival of stage T4N0-1 and single station IIIA-N2 NSCLC patients treated with definitive chemo-radiotherapy using individualised isotoxic accelerated radiotherapy (INDAR). Radiotherapy and Oncology. 110(3). 482–487. 19 indexed citations

10.

Oberije, Cary, Georgi Nalbantov, André Dekker, et al.. (2014). A prospective study comparing the predictions of doctors versus models for treatment outcome of lung cancer patients: A step toward individualized care and shared decision making. Radiotherapy and Oncology. 112(1). 37–43. 75 indexed citations

11.

Zegers, Catharina M.L., Wouter van Elmpt, Roel Wierts, et al.. (2013). Hypoxia imaging with [18F]HX4 PET in NSCLC patients: Defining optimal imaging parameters. Radiotherapy and Oncology. 109(1). 58–64. 69 indexed citations

12.

Lambin, Philippe, Erik Roelofs, Bart Reymen, et al.. (2013). ‘Rapid Learning health care in oncology’ – An approach towards decision support systems enabling customised radiotherapy’. Radiotherapy and Oncology. 109(1). 159–164. 136 indexed citations

13.

Elmpt, Wouter van, Marco Das, Martin Hüllner, et al.. (2013). Characterization of tumor heterogeneity using dynamic contrast enhanced CT and FDG-PET in non-small cell lung cancer. Radiotherapy and Oncology. 109(1). 65–70. 36 indexed citations

14.

Ruysscher, Dirk De, J. Belderbos, Bart Reymen, et al.. (2012). State of the Art Radiation Therapy for Lung Cancer 2012: A Glimpse of the Future. Clinical Lung Cancer. 14(2). 89–95. 36 indexed citations

15.

Baardwijk, Angela van, Wolfgang A. Tomé, Wouter van Elmpt, et al.. (2012). Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review. Radiotherapy and Oncology. 105(2). 145–149. 79 indexed citations

16.

Steevens, Jessie, Dirk De Ruysscher, Anita A.M. Botterweck, et al.. (2011). Also elderly patients (75 years or older) with stage III non-small cell lung cancer (nsclc) have survival gains with radical treatment: a prospective population-based study. Journal of Thoracic Oncology. 6(6). 1 indexed citations

17.

Baardwijk, Angela van, Bart Reymen, Rinus Wanders, et al.. (2011). Results of a phase II trial on individualized radiation dose-escalation based on normal tissue constraints in concurrent chemo-radiation for stage III non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 6(6).

18.

Ruysscher, Dirk De, Bart Reymen, & Angela van Baardwijk. (2011). High-Dose Hyperfractionated Accelerated Radiotherapy in Non-Small Cell Lung Cancer. PubMed. 66(4). 341–5. 2 indexed citations

19.

Ruysscher, Dirk De, Angela van Baardwijk, Jessie Steevens, et al.. (2011). Individualised isotoxic accelerated radiotherapy and chemotherapy are associated with improved long-term survival of patients with stage III NSCLC: A prospective population-based study. Radiotherapy and Oncology. 102(2). 228–233. 39 indexed citations

20.

Baardwijk, Angela van, Bart Reymen, Rinus Wanders, et al.. (2009). Individualized radiation dose escalation for stage I-III non-small cell lung cancer (NSCLC) based on normal tissue constraints: mature results of a phase II trial. Journal of Thoracic Oncology. 4(9). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact